Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Direct Immunofluorescence for Immunobullous and Other Skin Diseases Publisher Pubmed



Ghanadan A1, 2 ; Saghazadeh A3 ; Daneshpazhooh M4, 5 ; Rezaei N3, 6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathology, Razi Skin Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pathology, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Dermatology, Razi Skin Hospital, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, 14194, Iran
  7. 7. Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Expert Review of Clinical Immunology Published:2015


Abstract

A swift glance at ample evidence currently available about the assay clearly illustrates that the development of direct immunofluorescence (DIF), in which direct fluorescent antibodies are utilized to identify the target antigen, has been of immense importance. The immunoreactant deposits have been delineated by the DIF assay in three main locations, including throughout the epidermis, at the dermoepidermal junction (also known as the basement membrane zone) and in and/or around blood vessel walls. DIF testing can be conducted on several specimen sources, which are categorized according to feasibility of collection into invasive (e.g., skin) and non-invasive (e.g., hair). This review was intended to indicate that inspection of immunoreactant deposits via DIF is highly instrumental in diagnosing and monitoring the immunobullous and other diseases of the skin. © 2015 Informa UK, Ltd.
Related Docs
1. Immunologic Prediction of Relapse in Patients With Pemphigus Vulgaris (Pv) in Clinical Remission, Journal of the American Academy of Dermatology (2016)
2. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)
3. Loss of Normal Anagen Hair in Pemphigus Vulgaris, Clinical and Experimental Dermatology (2015)
4. International Bullous Diseases Group: Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita, British Journal of Dermatology (2018)
5. Comparative Analysis of Demographics and Clinical Outcomes in Patients With Pemphigus Vulgaris and Foliaceus With High Versus Normal Anti-Desmoglein Levels Post-Complete Remission, Archives of Dermatological Research (2025)
6. A Prospective Study of Laboratory Findings in Dapsone Treated Patients With Pemphigus Vulgaris and Foliaceus, Biomedical Research (India) (2017)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (4)
Hamid Reza Mahmoodi (2)